Artelo Biosciences, Inc. (ARTL) stock
ARTLNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.68−0.02 (-1.18%)
Close on Nov 17, 2026Market cap $1.13MP/E –Yield –
Artelo Biosciences cash
Cash and short-term investments held at the end of each period.
Artelo Biosciences's cash was $4.20M at Jun 30, 2026. For fiscal 2025 it was $600.00K, down 74.3% from the year before. Over ten years it grew 44.9% a year on average. The highest annual figure on record is $10.43M in fiscal 2023.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $600.00K | -74.3% |
| FY2024 | Dec 31, 2024 | $2.34M | -77.6% |
| FY2023 | Dec 31, 2023 | $10.43M | +3.6% |
| FY2021 | Aug 31, 2021 | $10.07M | +369.9% |
| FY2020 | Aug 31, 2020 | $2.14M | -51.6% |
| FY2019 | Aug 31, 2019 | $4.42M | +1211.1% |
| FY2018 | Aug 31, 2018 | $337.42K | -41.1% |
| FY2017 | Aug 31, 2017 | $572.78K | +15854.7% |
| FY2016 | Aug 31, 2016 | $3.59K | -78.9% |
| FY2015 | Aug 31, 2015 | $17.03K | +15.6% |
| FY2014 | Aug 31, 2014 | $14.73K | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $4.20M | +103.2% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $4.20M | +462.7% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $600.00K | -74.3% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $1.72M | -64.6% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $2.07M | -63.1% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $746.00K | -90.2% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $2.34M | -77.6% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $4.86M | -62.2% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $5.60M | -60.0% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $7.61M | -50.9% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $10.43M | +3.6% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $12.86M | +28.0% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $13.99M | +24.7% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $15.48M | +109.5% |
| Q4 FY2021CQ3 2021 | Aug 31, 2021 | $10.07M | +369.9% |
| Q3 FY2021CQ2 2021 | May 31, 2021 | $10.05M | +685.8% |
| Q2 FY2021CQ1 2021 | Feb 28, 2021 | $11.22M | +465.9% |
| Q1 FY2021CQ4 2020 | Nov 30, 2020 | $7.39M | +119.0% |
| Q4 FY2020CQ3 2020 | Aug 31, 2020 | $2.14M | -51.6% |
| Q3 FY2020CQ2 2020 | May 31, 2020 | $1.28M | +346.6% |
| Q2 FY2020CQ1 2020 | Feb 29, 2020 | $1.98M | +333.5% |
| Q1 FY2020CQ4 2019 | Nov 30, 2019 | $3.37M | +2832.6% |
| Q4 FY2019CQ3 2019 | Aug 31, 2019 | $4.42M | +1211.1% |
| Q3 FY2019CQ2 2019 | May 31, 2019 | $286.44K | -12.1% |
| Q2 FY2019CQ1 2019 | Feb 28, 2019 | $457.33K | -12.9% |
| Q1 FY2019CQ4 2018 | Nov 30, 2018 | $115.07K | -72.1% |
| Q4 FY2018CQ3 2018 | Aug 31, 2018 | $337.42K | -41.1% |
| Q3 FY2018CQ2 2018 | May 31, 2018 | $326.02K | +43.1% |
| Q2 FY2018CQ1 2018 | Feb 28, 2018 | $525.11K | +4718.8% |
| Q1 FY2018CQ4 2017 | Nov 30, 2017 | $412.44K | +11388.6% |
| Q4 FY2017CQ3 2017 | Aug 31, 2017 | $572.78K | +15854.7% |
| Q3 FY2017CQ2 2017 | May 31, 2017 | $227.84K | +6246.5% |
| Q2 FY2017CQ1 2017 | Feb 28, 2017 | $10.90K | +203.5% |
| Q1 FY2017CQ4 2016 | Nov 30, 2016 | $3.59K | -9.6% |
| Q4 FY2016CQ3 2016 | Aug 31, 2016 | $3.59K | -78.9% |
| Q3 FY2016CQ2 2016 | May 31, 2016 | $3.59K | -71.5% |
| Q2 FY2016CQ1 2016 | Feb 29, 2016 | $3.59K | – |
| Q1 FY2016CQ4 2015 | Nov 30, 2015 | $3.97K | – |
| Q4 FY2015CQ3 2015 | Aug 31, 2015 | $17.03K | – |
| Q3 FY2015CQ2 2015 | May 31, 2015 | $12.58K | – |
See a number that looks wrong?